OncoMatch/Clinical Trials/NCT06564272
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Is NCT06564272 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies KC1036 for ewing sarcoma.
Treatment: KC1036 — This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Demographics
Prior therapy
Must have received: standard treatment
has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator
Cannot have received: VEGFR-TKI small molecule
Patients who have previously received VEGFR-TKI small molecule treatment
Lab requirements
Blood counts
Sufficient organ and bone marrow function
Kidney function
Sufficient organ and bone marrow function
Liver function
Sufficient organ and bone marrow function
Sufficient organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06564272 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGFR-TKI small molecule disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages